JP2025509390A - カリプラジン又はその塩を含むデポシステム - Google Patents

カリプラジン又はその塩を含むデポシステム Download PDF

Info

Publication number
JP2025509390A
JP2025509390A JP2024553723A JP2024553723A JP2025509390A JP 2025509390 A JP2025509390 A JP 2025509390A JP 2024553723 A JP2024553723 A JP 2024553723A JP 2024553723 A JP2024553723 A JP 2024553723A JP 2025509390 A JP2025509390 A JP 2025509390A
Authority
JP
Japan
Prior art keywords
cariprazine
acid
composition
pharma
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024553723A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509390A5 (https=
Inventor
ルブノフ，シャイ
マロム，エフド
ゴピン，アンナ
Original Assignee
マピ ファーマ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マピ ファーマ リミテッド filed Critical マピ ファーマ リミテッド
Publication of JP2025509390A publication Critical patent/JP2025509390A/ja
Publication of JP2025509390A5 publication Critical patent/JP2025509390A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2024553723A 2022-03-17 2023-02-14 カリプラジン又はその塩を含むデポシステム Pending JP2025509390A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263320706P 2022-03-17 2022-03-17
US63/320,706 2022-03-17
PCT/IL2023/050150 WO2023175598A1 (en) 2022-03-17 2023-02-14 Depot systems comprising cariprazine or salts thereof

Publications (2)

Publication Number Publication Date
JP2025509390A true JP2025509390A (ja) 2025-04-11
JP2025509390A5 JP2025509390A5 (https=) 2026-02-24

Family

ID=88022782

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553723A Pending JP2025509390A (ja) 2022-03-17 2023-02-14 カリプラジン又はその塩を含むデポシステム

Country Status (9)

Country Link
US (2) US11931357B2 (https=)
EP (1) EP4493274A4 (https=)
JP (1) JP2025509390A (https=)
CN (1) CN119136804A (https=)
AU (1) AU2023234747A1 (https=)
CA (1) CA3244202A1 (https=)
IL (1) IL315074A (https=)
MX (1) MX2024011063A (https=)
WO (1) WO2023175598A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
US12514908B2 (en) 2021-07-05 2026-01-06 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
AU2023234747A1 (en) * 2022-03-17 2024-09-12 Mapi Pharma Ltd. Depot systems comprising cariprazine or salts thereof
US20230372331A1 (en) * 2022-05-18 2023-11-23 Anxo Pharmaceutical Co., Ltd. Pharmaceutical composition
CN119424341A (zh) * 2023-08-02 2025-02-14 珠海市华海康医药科技有限责任公司 一种注射用药物缓释微球及其制备方法
CN117137864A (zh) * 2023-11-01 2023-12-01 山东则正医药技术有限公司 一种卡利拉嗪原位凝胶制剂及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
US20090036468A1 (en) * 2007-08-03 2009-02-05 Forest Laboratories Holdings Limited Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands
US20090275597A1 (en) * 2008-05-02 2009-11-05 Forest Laboratories Holdings Limited Methods of treating cns disorders
WO2018015915A1 (en) * 2016-07-22 2018-01-25 Cadila Healthcare Limited A parenteral controlled release composition of an atypical antipsychotic agent
CN109982712A (zh) 2016-08-31 2019-07-05 Mapi医药公司 包含醋酸格拉替雷的储库系统
CN108261394B (zh) 2017-01-04 2022-03-04 广东东阳光药业有限公司 一种盐酸卡利拉嗪注射制剂及其制备方法和用途
HUP1700253A1 (hu) 2017-06-13 2019-01-28 Richter Gedeon Nyrt Szilárd orális gyógyszerkészítmények
US11344503B2 (en) * 2019-12-13 2022-05-31 Halo Science LLC Cariprazine release formulations
WO2022003662A1 (en) 2020-06-29 2022-01-06 Mapi Pharma Ltd. Low burst-release liraglutide depot systems
AU2023234747A1 (en) * 2022-03-17 2024-09-12 Mapi Pharma Ltd. Depot systems comprising cariprazine or salts thereof

Also Published As

Publication number Publication date
US11931357B2 (en) 2024-03-19
CN119136804A (zh) 2024-12-13
CA3244202A1 (en) 2023-09-21
EP4493274A1 (en) 2025-01-22
IL315074A (en) 2024-10-01
WO2023175598A1 (en) 2023-09-21
AU2023234747A1 (en) 2024-09-12
MX2024011063A (es) 2024-09-23
US20240238280A1 (en) 2024-07-18
US20230293515A1 (en) 2023-09-21
EP4493274A4 (en) 2026-03-18
US12251380B2 (en) 2025-03-18

Similar Documents

Publication Publication Date Title
US12251380B2 (en) Depot systems comprising cariprazine or salts thereof
JP2010505819A (ja) デポ型注射剤組成物とその調製方法
WO2009060473A2 (en) Injectable compositions, processes and uses thereof
CN1468090A (zh) 缓释药物制剂及其施用方法
EP2497476A1 (en) Aripiprazole pamoate salt
JP6249944B2 (ja) 注射製剤
US20220040201A1 (en) Liquid polymer delivery system for extended administration of drugs
US20240148653A1 (en) Semaglutide depot systems and use thereof
CN109414401B (zh) 用于胃肠外给药的生物可降解聚合物微球组合物
US20230256058A1 (en) Low burst-release liraglutide depot systems
WO2018108164A1 (zh) 一种硼替佐米药物组合物及其应用
JP6250005B2 (ja) 制御放出製剤
HK40116297A (zh) 包含卡利拉嗪或其盐的储库系统
CN1850035A (zh) 一种局部应用的抗生素的缓释制剂
TW202435885A (zh) 卡利拉嗪(Cariprazine)之長效性注射用(LAI)組合物
TW202529795A (zh) 新穎組成物
JP2025515960A (ja) 医薬組成物
CN1857218A (zh) 含抗结核病药物的缓释剂
CN1850036A (zh) 一种含喹诺酮类抗生素的缓释剂
TWI426929B (zh) 持續性釋放之含抗生素醫藥組合物、製備法及其應用
KR20250069077A (ko) 패티케이션 기술을 적용한 쿠에티아핀-지방산 접합체 나노입자 및 이의 장기 지속형 주사제 용도
CN101254169A (zh) 含抗结核病药物的缓释剂
HK40104236A (zh) 索玛鲁肽贮库系统及其用途
CN1846688A (zh) 同载紫杉烷及其增效剂的抗癌药物缓释剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260212